[go: up one dir, main page]

AU2002216346A1 - Cabergoline pharmaceutical compositions and methods of use thereof - Google Patents

Cabergoline pharmaceutical compositions and methods of use thereof

Info

Publication number
AU2002216346A1
AU2002216346A1 AU2002216346A AU1634602A AU2002216346A1 AU 2002216346 A1 AU2002216346 A1 AU 2002216346A1 AU 2002216346 A AU2002216346 A AU 2002216346A AU 1634602 A AU1634602 A AU 1634602A AU 2002216346 A1 AU2002216346 A1 AU 2002216346A1
Authority
AU
Australia
Prior art keywords
cabergoline
methods
pharmaceutical compositions
pharmaceutical
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002216346A
Inventor
David Caron
Malcolm Ross
Bosmat Rousso
Hava Schneider
Irena Ulanenko
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Par Pharmaceuticals Inc
Original Assignee
Par Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Par Pharmaceuticals Inc filed Critical Par Pharmaceuticals Inc
Publication of AU2002216346A1 publication Critical patent/AU2002216346A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2002216346A 2000-12-21 2001-12-18 Cabergoline pharmaceutical compositions and methods of use thereof Abandoned AU2002216346A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/740,955 US20020123503A1 (en) 2000-12-21 2000-12-21 Cabergoline pharmaceutical compositions and methods of use thereof
US09740955 2000-12-21
PCT/IL2001/001177 WO2002049608A1 (en) 2000-12-21 2001-12-18 Cabergoline pharmaceutical compositions and methods of use thereof

Publications (1)

Publication Number Publication Date
AU2002216346A1 true AU2002216346A1 (en) 2002-07-01

Family

ID=24978750

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002216346A Abandoned AU2002216346A1 (en) 2000-12-21 2001-12-18 Cabergoline pharmaceutical compositions and methods of use thereof

Country Status (3)

Country Link
US (1) US20020123503A1 (en)
AU (1) AU2002216346A1 (en)
WO (1) WO2002049608A1 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10053397A1 (en) * 2000-10-20 2002-05-02 Schering Ag Use of a dopaminergic active ingredient for the treatment of dopaminerg treatable diseases
DE10066158B4 (en) * 2000-08-24 2007-08-09 Neurobiotec Gmbh Use of a transdermal therapeutic system for the treatment of Restless Legs Syndrome
DE10064453A1 (en) * 2000-12-16 2002-07-04 Schering Ag Use of a dopaminergic active ingredient for the treatment of dopaminerg treatable diseases
SI21353A (en) * 2002-11-27 2004-06-30 Lek farmacevtska družba, d.d. Pellet-containing anhydrous liquids and process of their preparation
IL155545A (en) * 2003-04-21 2009-12-24 Finetech Pharmaceutical Ltd Solvate form of cabergoline
CA2525104A1 (en) * 2003-05-08 2004-11-25 Ivax Pharmaceuticals S.R.O. Polymorphs of cabergoline
WO2005102272A2 (en) * 2004-04-21 2005-11-03 Pfizer Products Inc. Sustained-release dosage forms for cabergoline
WO2007049626A1 (en) * 2005-10-27 2007-05-03 Kissei Pharmaceutical Co., Ltd. Oral solid preparation containing cabergoline
JP4691434B2 (en) * 2005-11-08 2011-06-01 東和薬品株式会社 Stabilized cabergoline solid formulation
EP2227224A2 (en) * 2007-12-17 2010-09-15 Pharmathen S.a. Improved pharmaceutical composition containing non-ergoline dopamine agonist and method for the preparation thereof
SG181896A1 (en) 2009-12-23 2012-07-30 Map Pharmaceuticals Inc Novel ergoline analogs
JP2014517076A (en) 2011-06-23 2014-07-17 マップ・ファーマシューティカルズ・インコーポレイテッド Novel fluoroergoline analogues
SG11201403434YA (en) 2011-12-19 2014-09-26 Map Pharmaceuticals Inc Novel iso-ergoline derivatives
US8946420B2 (en) 2011-12-21 2015-02-03 Map Pharmaceuticals, Inc. Neuromodulatory compounds
US9012640B2 (en) 2012-06-22 2015-04-21 Map Pharmaceuticals, Inc. Cabergoline derivatives
KR101766021B1 (en) * 2015-07-08 2017-08-10 (주)동구바이오제약 Pharmaceutical composition containing cabergoline having enhanced stability
CN114732791B (en) * 2022-03-17 2023-09-29 成都倍特药业股份有限公司 Composition containing cabergoline and preparation method and application thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811388A (en) * 1995-06-07 1998-09-22 Cibus Pharmaceutical, Inc. Delivery of drugs to the lower GI tract
US5980882A (en) * 1997-04-16 1999-11-09 Medeva Pharmaceuticals Manufacturing Drug-resin complexes stabilized by chelating agents
IL138522A0 (en) * 1998-03-27 2001-10-31 Upjohn Co Use of cabergoline in the treatment of restless legs syndrome

Also Published As

Publication number Publication date
WO2002049608A1 (en) 2002-06-27
US20020123503A1 (en) 2002-09-05

Similar Documents

Publication Publication Date Title
AU7362301A (en) Bioadhesive compositions and methods of preparation and use
AU2001241474A1 (en) Biosensor compositions and methods of use
AU2001285020A1 (en) P97-active agent conjugates and their methods of use
AU2609901A (en) Antimicrobial compositions and methods of use
AU2002230831A1 (en) Compositions of human proteins and method of use thereof
AU2001294808A1 (en) Catecholamine pharmaceutical compositions and methods
AU2002320058A1 (en) Magnetic-nanoparticle conjugates and methods of use
AU4520801A (en) Novel substituted phenanthridinones and methods of use thereof
AU2001280188A1 (en) Pyrazolopyridine compound and pharmaceutical use thereof
AU2001234437A1 (en) Deicing compositions and methods of use
AU2001244355A1 (en) Heterobiarylsulphonamides and their use as pde 7 inhibitors
AU2001294920A1 (en) Chrono delivery formulations and method of use thereof
AU2002225954A1 (en) Dipeptidylpeptidases and methods of use
AU2001281140A1 (en) Anti-plasmodium compositions and methods of use
AU5326100A (en) Pharmaceutical compositions and methods for use
AU2002216346A1 (en) Cabergoline pharmaceutical compositions and methods of use thereof
AU2001281850A1 (en) Use of inulin and inulin derivatives
WO2001041823A8 (en) Radioactive compositions and methods of use thereof
HUP0303731A3 (en) Sulfonylguanidines and their use for preparation of pharmaceutical compositions
AU2001293048A1 (en) Antiviral compositions and methods of use
AU2001230898A1 (en) Formulations and methods for administration of pharmacologically or biologicallyactive compounds
AU2001280721A1 (en) Compositions of iodonium compounds and methods and uses thereof
IL153487A0 (en) Pharmaceutical compositions and methods for use
AU2001247196A1 (en) Methods and compositions for detection of disease
AU2962400A (en) Cleaner composition and method of use thereof